Vertex Pharmaceuticals (VRTX) M&A announcement summary

Deal rationale and strategic fit

• Acquisition of Crinetics for $85 per share in cash, total equity value of ~$10B, aligns with focus on serious diseases with high unmet need and specialty markets, expanding into endocrinology and leveraging best-in-class assets.

• Crinetics' assets, PALSONIFY and atumelnant, offer best-in-class potential in rare endocrine diseases, strengthening the portfolio in acromegaly, CAH, and Cushing's syndrome.

• The deal adds endocrinology as a fifth pillar to the acquirer's commercial framework, diversifying beyond existing therapeutic areas.

• Crinetics' R&D platform and culture are highly synergistic with the acquirer's strengths in development and commercialization.

• The acquisition leverages global infrastructure to maximize the impact of acquired therapies and pipeline assets.

Financial terms and conditions

• All outstanding shares acquired for $85 per share in cash, total equity value ~$10B, or $8.8B net of estimated cash acquired.

• Financing through a mix of cash on hand and $4.5B fully committed bridge financing.

• Transaction unanimously approved by both Boards; expected to close in Q3 2026, subject to shareholder and regulatory approvals.

• Modest impact to 2026 revenue and non-GAAP operating expenses; accretive to non-GAAP operating income expected in 2029.

Synergies and expected cost savings

• Significant commercial synergies expected due to overlap in specialty endocrinology prescriber base and leveraging acquirer's operating leverage strategy.

• Vertex's capabilities anticipated to accelerate launches and pipeline development for Crinetics' assets.

• High operating margins and significant cash flow expected from oral, small molecule endocrinology products.

• Immediate revenue growth expected from the ongoing launch of a key commercial product.

• Long-term potential for over $5B in combined annual revenue from acquired assets.